Treatment Trials

1 Clinical Trials for Various Conditions

Focus your search

      TERMINATED
      Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI Failure
      Description

      This phase II trial studies how well bosutinib works in treating patients with chronic myeloid leukemia in chronic phase after frontline tyrosine kinase inhibitor (TKI) failure. Bosutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

      Conditions
      Blasts Under 15 Percent of Bone Marrow Nucleated CellsBlasts Under 15 Percent of Peripheral Blood White CellsBlasts Under 30 Percent of Bone Marrow Nucleated CellsBlasts Under 30 Percent of Peripheral Blood White CellsChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
      Talk to us